No Data
Wall Street Today: Market Pulls Back After Wild Week
Stocks Stall, Gold Nears Record Highs As Dollar Faces Worst Week Since July 2023: What's Driving Markets Friday?
U.K. Pharma Group Criticizes Novo Over Patient Payments: Report
Live Stock: First Week Down, Market Pulls Back a Hair After Records
Customers Bancorp, Twilio, Dana And Other Big Stocks Moving Higher On Friday
Novo-Nordisk A/S once surged over 10% due to impressive trial data for the new weight-loss drug Amycretin.
① Novo-Nordisk A/S announced the latest trial results of its new weight loss drug Amycretin, which can help patients lose an average of 22%, better than the company's currently sold Semaglutide; ② The Amycretin drug may help Novo-Nordisk A/S compete with its major rival Eli Lilly and Co.
SuIIIIT OP : Not to ball